Q1 2024 Earnings Forecast for LENZ Therapeutics, Inc. (NASDAQ:LENZ) Issued
By Leerink Partnrs
Related Articles
-
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $25.00 by Analysts at HC Wainwright
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price objective reduced by stock analysts at HC Wainwright from $28.00 to $25.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside […]
-
Everence Capital Management Inc. Purchases 2,700 Shares of Intuit Inc. (NASDAQ:INTU)
Everence Capital Management Inc. boosted its position in shares of Intuit Inc. (NASDAQ:INTU – Free Report) by 44.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,830 shares of the software maker’s stock after purchasing an additional 2,700 shares during the quarter. Everence […]
-
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2.8% After Analyst Upgrade
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) rose 2.8% during mid-day trading on Thursday after Citigroup raised their price target on the stock from $88.00 to $89.00. Citigroup currently has a buy rating on the stock. CRISPR Therapeutics traded as high as $57.19 and last traded at $57.11. Approximately 273,490 shares changed […]